Since bevacizumab only targets VEGF-A, the presence of high levels of VEGFR-1 and -2 proteins in tumor tissue and their circulating sVEGFR proteins may compete with bevacizumab for VEGF-A binding, resulting in drug resistance. This evidence concerns the gene FLT1 and neoplasm.